Growth Interrupted: Sustaining The Israeli Life Science Innovation Engine
Maximizing the productivity of life science innovation hubs across the globe is of ever increasing importance to the continued vitality of the life science products industry. Israel's culture of innovation has produced a large number of start-up companies and product ideas, particularly in medical devices, but Israel has developed remarkably few mature life science companies. One major historical factor preventing Israeli start-ups from maturing into later stage companies is the absence of significant growth capital necessary to finance this kind of company development, which has lead to what the authors term an ongoing market failure. The authors argue that both private and public action is necessary to address this market failure in Israel, and that such action will benefit both that country and the industry as a whole by maintaining this fertile source of life science innovation.
You may also be interested in...
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.
Sandoz sees key opportunities ahead in both the US and Canadian biosimilars markets, the firm’s US vice-president for marketing, market access and patient services, Sheila Frame, tells Generics Bulletin in the second part of an exclusive interview.
As the final scheduled round of post-Brexit trade talks begins amid growing concern over the prospect of a deal and the pervasive threat of COVID-19, the pharmaceutical industry in the UK and the EU have issued an urgent call for an MRA on medicines GMP. They also want to see a one-year phase-in of medicines-related aspects of the Northern Ireland Protocol.